Camilla M. Ribeiro

Sao Paulo, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Treatment of supratrochlear and supraorbital veins with long-pulsed 1064-nm Nd: YAG laser: A single-arm prospective pilot study.

Treatment of supratrochlear and supraorbital veins with long-pulsed 1064-nm Nd: YAG laser: A single-arm prospective pilot study.

Journal: Phlebology

Published: January 06, 2026

Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent Claudication.

Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent Claudication.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: October 23, 2025

Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial).

Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial).

Journal: Phlebology

Published: September 04, 2025

Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain.

Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain.

Journal: Annals of medicine

Published: July 11, 2025

Pharmacokinetic analysis of 25 mg estradiol subcutaneous bioabsorbable implant in postmenopausal women (CLARA STUDY).

Pharmacokinetic analysis of 25 mg estradiol subcutaneous bioabsorbable implant in postmenopausal women (CLARA STUDY).

Journal: Menopause (New York, N.Y.)

Published: April 28, 2025

Pigmentation after foam or cryo-laser cryo-sclerotherapy for lower limb reticular veins: A within-patient randomized trial.

Pigmentation after foam or cryo-laser cryo-sclerotherapy for lower limb reticular veins: A within-patient randomized trial.

Journal: Journal of vascular surgery. Venous and lymphatic disorders

Published: April 23, 2025

Rivaroxaban for Patients with Intermittent Claudication.

Rivaroxaban for Patients with Intermittent Claudication.

Journal: NEJM evidence

Published: August 26, 2024

Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial.

Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial.

Journal: Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica

Published: April 15, 2024

Biomarkers Profile in Provoked Versus Unprovoked Deep Venous Thrombosis.

Biomarkers Profile in Provoked Versus Unprovoked Deep Venous Thrombosis.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: April 03, 2024

Effects of long-pulsed 1064-nm Nd:YAG laser on telangiectasias and reticular veins: a human in-vivo histological study.

Effects of long-pulsed 1064-nm Nd:YAG laser on telangiectasias and reticular veins: a human in-vivo histological study.

Journal: International angiology : a journal of the International Union of Angiology

Published: November 16, 2023

Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study.

Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study.

Journal: Lancet regional health. Americas

Published: January 10, 2023

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial).

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial).

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: December 07, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026